11 September 2019 01:30pm - 02:30pm Australia/Sydney
This session will discuss the increasing use of Faecal Microbiota Transplantation (FMT) in treating gastrointestinal conditions. Collection and preparation of FMT material is a developing area but regulatory and bureaucratic issues remain unresolved.
|Presenter:||Michael Thomas, Microbiology Medical Specialist, Australian Red Cross Blood Service.|
29 March 2017 01:30pm - 02:30pm - Australia/Melbourne
This session focuses on the immunology as one of the new dimensions in providing compatible platelets. The background science and testing processes are discussed followed by how it is applied to patient care in the renal setting.
Rhonda Holdsworth, National Manager, Transplantation and Immunogenetics Services, Blood Service
Cathie Hart, Deputy Manager, VTIS, Blood Service.
9 March 2016 01:30pm - 2:30pm - Australia/Melbourne
Transfusion support for patients with renal disease requires expert medical and scientific involvement while they are managed on transplantation waiting lists and are undergoing dialysis. Optimising haemostasis as well as avoiding development of further HLA antibodies requires dialysis transplantation, transfusion medicine and patient blood management expertise.
|Presenters:||A/Prof Shlomo Cohney, Transplant Physician, University of Melbourne & Monash University|
|Dr Jeremy McComish, Clinical Immunologist, Allergist and Immunopathologist, Blood Service.|
2 September 2020 01:30pm - 02:30pm Australia/Sydney
This presentation will cover the basic immunogenetics involved in transplantation matching and how we use HLA epitope science to fine tune the degree of matching at the immune response level.
HLA antibodies are a contraindication in transplantation and many recipients have pre formed antibodies from previous transplants, pregnancy and transfusion. Finding a suitable match for these patients is challenging and we have employed a newly established approach using HLA epitope science to refine the immunology. Typically this process has been used for highly sensitised patients but has now been applied pre-emptively in paediatric patients for their first transplant to stop any future antibodies.
|Presenter:||Ms Rhonda Holdsworth, National Manager, Transplantation and Immunogenetics Services, Australian Red Cross Lifeblood.|